Study population
Patients implanted with the Micra Transcatheter Pacing System
(Medtronic, Minneapolis, MN, USA), from 9 major tertiary European LPM
implanting centers, between September 2015 and August 2019 (4 years),
and followed in the Micra Transcatheter Pacing System Post-Approval
Registry (NCT02536118) were retrospectively screened.
Inclusion criteria were: patients with an indication of prolonged
cardiac pacing, who underwent an LPM implantation during the
hospitalization in an ICU; and the presence of at least one of the
following: ≥1 supracaval central venous line (including hemodialysis
catheter), or a ventilation tube, or intravenous antibiotic therapy for
ongoing sepsis or bacteremia. Exclusion criteria were: previous
implantation of a pacemaker. This study was conducted in accordance with
the amended Declaration of Helsinki, and written informed consent was
obtained from all patients or their substitute decision-makers.
Data on clinical characteristics of patients, especially comorbidities,
LPM implantation procedure, duration of hospitalization were collected.
Patients had regular cardiovascular consultation including LPM
interrogation of electrical parameters (≥1 per year).